Trial Profile
An Open-Label, Dose Escalation, Cohort Study to Determine the Maximum Tolerated Dose and Safety of PEP005 Topical Gel When Applied on Day 1 and Day 2 to Actinic Keratoses on the Shoulders, Chest, Back or Arms Followed by a Post-Treatment Follow-up Period Lasting at Four Weeks
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Mar 2015
Price :
$35
*
At a glance
- Drugs Ingenol mebutate (Primary)
- Indications Actinic keratosis
- Focus Adverse reactions
- Sponsors Peplin
- 11 Dec 2014 New trial record